Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
Antimicrobial Agents and Chemotherapy|December 14, 2016
Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected PatientsElodie Valade, Naïm Bouazza, Gabrielle Lui, et al.
The Journal of Antimicrobial Chemotherapy|July 4, 2019
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL studyChristine Katlama, Lambert Assoumou, Marc-Antoine Valantin, et al.
The Lancet. HIV|February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trialGraeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
BMC Infectious Diseases|June 13, 2022
Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort studyGuillaume Martin-Blondel, François-Xavier Lescure, Lambert Assoumou, et al.
AIDS (London, England)|April 23, 2025
Cost-effectiveness of a 4 days-a-week triple therapy in persons living with HIV: an ancillary study of the QUATUOR trialGilles Hejblum, Samih Daher, Paul Moulaire, et al.
HIV Medicine|August 7, 2025
Morbidity and risk factors of COVID-19 in people with HIV-1 in Europe: A combined observational cohort and nested case-control studyGeorg M N Behrens, Lambert Assoumou, Stephane De Wit, et al.
The Lancet. Infectious Diseases|May 26, 2024
Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial designJean-Michel Molina, Beatrice Bercot, Lambert Assoumou, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
The Journal of Antimicrobial Chemotherapy|April 18, 2015
HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategiesPierre Frange, Lambert Assoumou, Diane Descamps, et al.
The Journal of Antimicrobial Chemotherapy|April 8, 2020
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial)Cathia Soulie, Lambert Assoumou, Basma Abdi, et al.
Pageof 13